NASDAQ: DARE · Life Sciences · 5 alerts · CIK 1401914
Share price
$0.5842Close, Nov 16
Market cap
$11.5M
Shares outstanding
19.67MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Dare Bioscience, Inc. filings on SEC EDGAR ↗
Insight Molecular Diagnostics (iMDx) reported Q3 2026 financial results, highlighting revenue of $559,000 and progress on its FDA de novo submission for GraftAssureDx. The company also announced the initiation of patient enrollment in its GALACTIC registry study at UCLA Medical Center and the appointment of a new transplant sales leader to prepare for commercial launch.
For the nine months ended September 30, 2026, Dare Bioscience reported a net loss of $9.14 million, an improvement from the $11.96 million loss in the prior year period. The company expanded its business model to include a dual-path approach for market access via 503B outsourcing facilities while continuing traditional FDA approval pathways.
Stockholders of Daré Bioscience approved the potential future issuance of common stock upon the exercise of outstanding warrants in accordance with Nasdaq listing rules. The approval was obtained at a special meeting held on November 10, 2026, ensuring compliance with dilution limits for a previously initiated capital raise.
Daré Bioscience received a deficiency notice from Nasdaq on September 28, 2026, because its common stock closing bid price fell below the $1.00 minimum requirement for 30 consecutive business days. The company has until March 29, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. The notice has no immediate effect on the listing, and the company may be eligible for an additional 180-day compliance period if necessary.
Daré Bioscience, Inc. filed a corporate presentation dated October 1, 2026, as an exhibit to its 8-K. The company intends to use this presentation in meetings with securities market participants and has made it available on its investor relations website.